Barron Associates has developed the “Remote Oxygen Adherence Monitor” (ROAM) to reliably assess long term oxygen therapy (LTOT) adherence. LTOT is associated with significant reductions in hospitalizations and improved quality of life in patients with chronic obstructive pulmonary disease (COPD). Despite the benefits of LTOT, adherence remains a challenge in the majority of patients. The ROAM system uses innovative sensors and classification algorithms to provide an accurate method for measuring patient LTOT usage. The system also includes motivational encouragement to promote improved adherence. Barron Associates has commenced validation studies with COPD patients to assess the accuracy of the ROAM system at classifying oxygen usage under multiple conditions.